English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Genetic modifiers are important clues for the identification of therapeutic targets in neurodegenerative diseases. Huntington disease (HD) is one of the most common autosomal dominant inherited neurodegenerative diseases. The clinical symptoms include motor abnormalities, cognitive decline and behavioral disturbances. Symptom onset is typically between 40 and 50 years of age, but can vary by several decades in extreme cases and this is in part determined by modifying genetic factors. The metabolic master regulator PGC-1α, coded by the  PPARGC1A  gene, coordinates cellular respiration and was shown to play a role in neurodegenerative diseases, including HD.    Methods  Using a candidate gene approach we analyzed a large European cohort (n = 1706) from the REGISTRY study for associations between  PPARGC1A  genotype and age at onset (AO) in HD.    Results  We report that a coding variant (rs3736265) in  PPARGC1A  is associated with an earlier motor AO in men but not women carrying the HD mutation.    Conclusions  These results further strengthen the evidence for a role of PGC-1α in HD and unexpectedly suggest a gender effect.

bmc neurology

A single nucleotide polymorphism in the coding region of PGC-1α is a male-specific modifier of Huntington disease age-at-onset in a large European cohort